Published in final edited form as:

Inflamm Bowel Dis. 2008 July ; 14(7): 908–920.

Hepatocyte nuclear factor 4 α in the intestinal epithelial cells protects against inflammatory bowel disease

Sung-Hoon Ahn¹, Yatrik M. Shah¹, Junko Inoue¹, Keiichiro Morimura^{1,2}, Insook Kim¹, SunHee Yim¹, Gilles Lambert³, Reiko Kurotani^{1,4}, Kunio Nagashima⁵, Frank J. Gonzalez¹, and Yusuke Inoue^{1,6}

¹ Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892

² Department of Pathology, Osaka City University Medical School, Osaka 545-8585, Japan

³ Universite de Nantes, Inserm U539, CHU Hotel-Dieu, Nantes 44035, France and The Heart Research Institute, Camperdown, NSW 2050, Australia

⁴ Cardiovascular Research Institute, Yokohama City University, Yokohama 236-0004, Japan

⁵ Image Analysis Laboratory, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702

⁶ Department of Chemistry and Chemical Biology, Graduate School of Engineering, Gunma University, Kiryu, Gunma 376-8515 Japan

Abstract

Background—Hepatocyte nuclear factor 4 α (HNF4 α ; NR2A1) is an orphan member of the nuclear receptor superfamily expressed in liver and intestine. While HNF4 α expression is critical for liver function, its role in the gut and in the pathogenesis of inflammatory bowel disease (IBD) is unknown.

Methods—Human intestinal biopsies from control and IBD patients were examined for expression of mRNAs encoding HNF4 α and other nuclear receptors. An intestine-specific HNF4 α null mouse line (*Hnf4 α ^{ΔIEpC}*) was generated using an *Hnf4 α* -floxed allele and villin-Cre transgene. These mice and their control floxed counterparts (*Hnf4 α ^{F/F}*), were subjected to a dextran sulfate sodium (DSS)-induced IBD colitis protocol and their clinical symptoms and gene expression patterns determined.

Results—In human intestinal biopsies, HNF4 α was significantly decreased in intestinal tissues from Crohn's disease and ulcerative colitis patients. HNF4 α expression was also suppressed in the intestine of DSS-treated mice. In *Hnf4 α ^{ΔIEpC}* mice, disruption of HNF4 α expression was observed in the epithelial cells throughout intestine. In the DSS-induced colitis model, *Hnf4 α ^{ΔIEpC}* mice showed markedly more severe changes in clinical symptoms and pathologies associated with IBD including loss of body weight, colon length, and histological morphology, as compared with *Hnf4 α ^{F/F}* mice. Furthermore the *Hnf4 α ^{ΔIEpC}* mice demonstrate a significant alteration of mucin associated genes and increase intestinal permeability, which may play an important role in the increased susceptibility to acute colitis following an inflammatory insult.

Conclusions—While HNF4 α does not have a major role in normal function of the intestine, it protects the gut against DSS-induced colitis.

INTRODUCTION

Inflammatory bowel disease (IBD) is a group of inflammatory conditions of the large intestine and small intestine, including Crohn's disease (CD) and ulcerative colitis (UC) (1,2). The etiology of IBD is still not fully understood, however nuclear receptors have been shown to be critical in the pathogenesis of IBD; vitamin D receptor (VDR) (3,4), peroxisome proliferator-activated receptor (PPAR) γ (5–7), PPAR α (8), PPAR δ (9), pregnane X receptor (PXR) (10, 11), and glucocorticoid receptor (GR) (12,13) have been shown to influence the severity of IBD symptoms in experimental models. Interestingly, the relationship between the liver and gut-enriched nuclear receptor, hepatocyte nuclear factor 4 α (HNF4 α) and IBD has remained unexplored.

HNF4 α , an orphan member of the nuclear receptor superfamily (NR2A1) (14,15), is expressed in liver, kidney, small intestine, colon, and also to some degree in pancreas (16,17). *Hnf4 α* -null mice were shown to be embryonic lethal (18), indicating that HNF4 α is an essential transcription factor during embryonic development. To assess the function of HNF4 α gene in adult liver, liver-specific *Hnf4 α* -null mice were established using the Cre-loxP method with albumin-Cre transgenic mice that specifically express the Cre gene in hepatocytes under the control of the rat albumin promoter (19). In liver, HNF4 α was found to be critical in lipid, glucose, ammonia, and amino acid metabolism, and in the production of bile acids and blood coagulation via regulation of several liver-specific genes (19–24). Pancreatic β cell-specific *Hnf4 α* -null mice were generated using rat insulin 2 gene promoter-regulated Cre transgenic mice (25). These mice exhibited impaired glucose-stimulated insulin secretion as well as human maturity onset diabetes of the young 1 (MODY1), but did not develop diabetes. However, another line of β cell-specific *Hnf4 α* -null mice exhibited hyperinsulinemia and hypoglycemia (26). The discrepancies between two lines might be explained by differences in deleted exons flanked by loxP sites (exon 2, or exon 4 and 5, respectively) or genetic background.

Similar to hepatic HNF4 α , HNF4 α in the gut was reported to regulate the expression of many genes such as apolipoprotein A-I, A-IV, B, guanylyl cyclase C, CYP3A4, intestinal alkaline phosphatase, and meprin 1 α in intestinal cells (27–33). Recently, embryo colon-specific *Hnf4 α* -null mice were generated using Cre-loxP method with Foxa3-Cre transgenic mice (34). These mice revealed an essential role for HNF4 α in development of the colon. However, the role of HNF4 α in the adult gastrointestinal tract remains unknown.

In the current study, HNF4 α expression was significantly decreased in IBD patients. To assess the function of HNF4 α in adult intestine, an intestinal epithelial cell-specific *Hnf4 α* -null mouse line was produced using Cre transgenic mice in which the Cre gene is expressed in the intestine under the control of the mouse villin promoter (35). The intestine-specific *Hnf4 α* -null mice exhibited increased susceptibility to DSS-induced IBD including increased intestinal permeability. These findings suggest that HNF4 α may have an important role in the etiology of IBD.

MATERIALS AND METHODS

Human IBD samples

To assess nuclear receptor gene expression in human IBD patient tissues, TissueScan Tissue qPCR Arrays Panels of human IBD patients were purchased from OriGene Technologies, INC. (Rockville, MD). The cDNAs per each panel were composed of 6 normal, 21 CD, and 21 UC patients (Table 1).

Generation of intestine-specific *Hnf4a*-null mice

Intestinal epithelial cells-specific *Hnf4a*-null mice, designated *Hnf4a*^{ΔIEpC}, were generated by crossing *Hnf4a*-floxed mice, designated *Hnf4a*^{F/F} (19) with mice carrying the villin-Cre transgene (35). Villin-cre transgenic mice were provided by Deborah L. Gumucio, University of Michigan. Cre-mediated recombination results in removal of exons 4 and 5 of the *Hnf4a* gene. The (*Hnf4a*^{flox/WT}; Villin-Cre⁺) F₁ mice were interbred with *Hnf4a*^{flox/flox} littermates lacking Villin-Cre. All mice were genotyped by PCR, and *Hnf4a*^{flox/flox}; Villin-Cre⁺ (designated *Hnf4a*^{ΔIEpC}) and *Hnf4a*^{flox/flox}; Villin-Cre⁻ (*Hnf4a*^{F/F}) mice were used for the following experiments. PCR genotyping for *Hnf4a* floxed and recombined alleles, and the Cre/microsomal epoxide hydrolase (mEH) gene was carried out as described previously (19). All experiments were performed with 2-month-old *Hnf4a*^{F/F} and *Hnf4a*^{ΔIEpC} mice. To assure genetic homogeneity between the *Hnf4a*^{F/F} and *Hnf4a*^{ΔIEpC} mice, they were interbred for more than ten generations and littermates used in all experiments. Mice were housed in a pathogen-free animal facility under standard 12 hr light/12 hr dark cycle with ad libitum water and chow. All experiments with mice were carried out under Association for Assessment and Accreditation of Laboratory Animal Care guidelines with approval of the NCI Animal Care and Use Committee.

Northern blot analysis

Northern blot analysis was carried out as described previously (20). All probes were amplified from a mouse liver cDNA library using gene-specific primers and cloned into pCR II vector (Invitrogen, Carlsbad, CA). Sequences were verified using CEQ 2000 Dye Terminator cycle sequencing kit (Beckman Coulter, Fullerton, CA) with a CEQ 2000XL DNA Analysis System (Beckman Coulter).

Quantitative real-time PCR

Total RNA was isolated from each mouse tissues using Trizol reagent (Invitrogen) and was reverse-transcribed using random hexamers and Superscript II reverse transcriptase (Invitrogen). Quantitative real-time PCR (qPCR) was performed on an ABI PRISM 7900HT sequence detection system (Applied Biosystems, Foster City, CA) and PCR primers designed by Primer Express (Applied Biosystems). Purified cDNAs were amplified using SYBR Green PCR Master Mix (Applied Biosystems) and 0.3 mM specific oligonucleotide primers. The sequence and Genbank accession numbers for the primers used to quantify mRNAs in this study are available on request. PCR was performed at 95°C for 10 minutes followed by 40 cycles of 15 s at 95°C and 1 min at 60°C. Efficient amplification of each mRNA was confirmed using a cDNA dilution series. For each sample, the mean threshold cycle (Ct) from two replicate PCR using RNA isolated from independent colons was taken. Expression levels of mRNA were normalized to 36B4 RNA as internal standard by the comparative method. All values are expressed as the mean ± standard deviation.

Western blot analysis

Frozen colon tissues were gently homogenized in a glass tube with a manual pestle, and nuclear and cytoplasmic extracts were prepared using NE-PER nuclear and cytoplasmic extraction reagents (Pierce, Rockford, IL), with the addition of proteinase inhibitors (Roche inhibitor mixture set I and 1 mM phenylmethylsulfonyl fluoride). Nuclear or cytoplasmic protein (15–50 μg) was subjected to SDS-polyacrylamide gel electrophoresis (10–12.5%), followed by transfer to a polyvinylidene difluoride membrane (Amersham Biosciences, Piscataway, NJ). The membrane was incubated with phosphate-buffered saline containing 0.1% Tween 20 and 5% dry milk for 1 h and then overnight with a primary antibody against HNF4α (dilution 1:500) (Santa Cruz Biotechnology, Santa Cruz, CA) and β-actin (dilution 1:10,000) (Santa Cruz Biotechnology). After washing, the membrane was incubated with a 1:5,000 diluted

peroxidase-conjugated secondary antibody (Santa Cruz Biotechnology), and the product was visualized using a chemiluminescent system (Super Signal West Pico Chemiluminescent Substrate; Pierce). The gels were scanned, and the bands were quantified by analysis of tagged image files using Image/J 1.36b software (Research Services Branch, National Institute of Mental Health, National Institutes of Health). The β -actin signals were used as loading controls for quantifying expression of HNF4 α . The expression of HNF4 α in HepG2 cell was used as positive control.

Histological and immunohistochemical analysis

Duodenum, jejunum, ileum, and colon from 2-month-old *Hnf4 α ^{F/F}* and *Hnf4 α ^{Δ IEpC}* mice were fixed in 10% neutral buffered formalin and embedded in paraffin, and sections cut at a thickness of 3 μ m were stained with hematoxylin and eosin (H&E), Alcian Blue (Sigma-Aldrich), and periodic acid-Schiff (PAS) (Sigma-Aldrich). Pieces of colon were fixed in 2.5% glutaraldehyde and postfixed in osmium tetroxide, and thin sections were stained with uranyl nitrate and lead citrate for the ultrastructural study. Immunohistochemical analysis was performed using antibody directed against HNF4 α (Santa Cruz Biotechnology).

Induction and assessment of experimental DSS-induced IBD

To study the role of HNF4 α in IBD, 2-month-old *Hnf4 α ^{F/F}* and *Hnf4 α ^{Δ IEpC}* mice (n=14 for each group) were administered 2.5% DSS in the drinking water for five days. Daily changes in body weight and clinical signs of colitis, such as rectal bleeding, diarrhea, and bloody stool, were assessed and reported as a score from 0 to 4. At day 5 after DSS treatment, the mice were killed and colon tissues collected for histological study and mRNA gene expression. For histological analysis, colon tissue samples were H&E stained and histology score was analyzed (36). Other detailed experimental methods of DSS-induced IBD were described in previous reports (7,37).

In vivo intestinal permeability in DSS-induced IBD

Intestinal permeability was assayed in *Hnf4 α ^{F/F}* and *Hnf4 α ^{Δ IEpC}* mice using a FITC-labeled-dextran method, as described previously (11). Untreated and three-day DSS treated mice were gavaged with 0.6 mg/g body weight of fluorescein isothiocyanate (FITC)-dextran solution (mol wt 4,000, at a concentration of 60 mg/ml; Sigma-Aldrich). Blood samples were collected from each group at 2 hr and 4 hr after FITC-dextran administration (n=4 for each group). A fluorescent unit of FITC-dextran in blood plasma was measured using fluorescent detection method.

Statistical analysis

All data are expressed as the mean $\pm$ SD. Statistical significance was determined by the Student *t* test for unpaired samples. For the analysis of human IBD patient data, Mann-Whitney U test was performed to assess differences between normal and patients group. P values are expressed as *, $P<0.05$, ** $P<0.01$, and ***, $P<0.001$.

RESULTS

Gene expression analysis for nuclear receptors in IBD patients

Gene expression analysis was performed for HNF4 α , farnesoid X receptor (FXR), liver X receptor (LXR), mineralocorticoid receptor (MR), peroxisome proliferator-activated receptor α , β , γ (PPAR α , PPAR β , PPAR γ), vitamin D receptor (VDR), and pregnane X receptor (PXR) in intestinal samples from IBD patients (Fig. 1). The levels of mRNA encoding HNF4 α , MR, PPAR γ , and PXR was significantly decreased in intestinal samples from IBD patients compared to healthy controls, whereas no difference was observed in gene expression of LXR,

PPAR α , PPAR β , and VDR. Interestingly, HNF4 α gene expression was significantly downregulated in both CD and UC patients suggesting HNF4 α may play an important role in the pathogenesis of IBD.

HNF4 α gene expression was decreased in experimental DSS-induced IBD

To investigate the role of HNF4 α in experimental DSS-induced IBD, C57BL/6N mice were exposed to 2.5% or 5% (wt/vol) DSS for 7 days. The expression of HNF4 α mRNA was markedly decreased, over 90% inhibition in experimental DSS-induced IBD samples (Fig. 2). Compared with untreated mice, both 2.5% DSS and 5% DSS treatment resulted in decreased HNF4 α mRNA expression as revealed by quantitative real-time PCR (qPCR) (Fig. 2A). To investigate the time dependence on decreased HNF4 α gene expression after DSS treatment, mice were killed and colon tissues were collected at day 1, 3, 5, and 7 following 2.5% DSS treatment. HNF4 α mRNA expression was significantly decreased as early as day 1 following DSS administration (Fig. 2B). Consistent with these data, HNF4 α protein levels were decreased (Fig. 2C) after 2.5% DSS treatment and the relative band density of HNF4 α compared with β -actin was also decreased as early as day 1 after treatment (Fig. 2D). Therefore, these data suggest a role of HNF4 α in an acute colon inflammatory model. To further investigate the role of HNF4 α in colon inflammation, gut-specific conditional knockout mice were generated and examined.

Generation of intestinal epithelial cells-specific *Hnf4 α* ^{Δ IEpC} mice

Intestinal epithelial cell-specific *Hnf4 α* -null mice were produced by crossing mice homozygous for *Hnf4 α* -floxed alleles (*Hnf4 α* ^{flox/flox}) with villin-cre transgenic (Villin-Cre) mice (Fig 3A). The genotype was confirmed using PCR with primers specific for the *Hnf4 α* floxed allele and Cre gene (Fig 3B). To assess the loss of HNF4 α gene expression, northern blot analysis was performed using total RNA from 2-month-old *Hnf4 α* ^{F/F} and *Hnf4 α* ^{Δ IEpC} mice (Fig. 3C). HNF4 α mRNA in *Hnf4 α* ^{F/F} mice was detected in all tissues examined, including liver, kidney, duodenum, jejunum, ileum, and colon (left panel, L, K, D, J, I, and C, respectively). In *Hnf4 α* ^{Δ IEpC} mice (right panel), loss of HNF4 α mRNA was observed in duodenum, jejunum, ileum and colon, but not in liver and kidney. This result indicates that *Hnf4 α* ^{Δ IEpC} mice recombine the floxed allele specifically in intestinal epithelial cells. *Hnf4 α* ^{Δ IEpC} mice were viable and their growth rates normal when compared to *Hnf4 α* ^{F/F} mice. By immunohistochemical analysis using HNF4 α antibody, HNF4 α protein was detected in the epithelial cells of duodenum, jejunum, ileum and colon of *Hnf4 α* ^{F/F} mice (Fig. 3D; a, c, e, and Fig. 4C), but not in *Hnf4 α* ^{Δ IEpC} mice (Fig. 3D; b, d, f, and Fig. 4C), in agreement with results of mRNA expression.

Histological and immunohistochemical analysis of *Hnf4 α* ^{Δ IEpC} mice

To determine the effect of HNF4 α disruption on intestinal epithelial cell morphology, histology was investigated (Fig. 4). H&E staining was produced in the duodenum (Fig. 4A; a and b), jejunum (Fig. 4A; c and d), ileum (Fig. 4A; e and f), and colon (Fig. 4A; g and h) between *Hnf4 α* ^{F/F} and *Hnf4 α* ^{Δ IEpC} mice. In addition, since HNF4 α was shown to be critical in embryonic development of the mouse colon (34), ultrastructure of the colon in *Hnf4 α* ^{Δ IEpC} mice was studied by electron microscopy. Colon epithelial cells in both *Hnf4 α* ^{F/F} and *Hnf4 α* ^{Δ IEpC} mice were generally intact and no significant damages in sub-cellular organelles were noted. However, significant numbers of mucous granules were found in the epithelial cells of *Hnf4 α* ^{Δ IEpC} mice compared to *Hnf4 α* ^{F/F} mice (Fig. 4B). In order to investigate biochemical differences in colon of *Hnf4 α* ^{Δ IEpC} mice, PAS and Alcian blue stain was performed for detection of polysaccharides including neutral mucopolysaccharides, and acidic mucopolysaccharides, respectively (Fig. 4C). The intensity of PAS staining in *Hnf4 α* ^{Δ IEpC} mouse gut was weaker than that in *Hnf4 α* ^{F/F} mice (Fig. 4C; m and n); the same result was

obtained by Alcian blue staining (Fig. 4C; o and p), indicating that secretion of mucous from goblet cells may be reduced in the colon of *Hnf4a*^{ΔIEpC} mice.

Susceptibility of *Hnf4a*^{ΔIEpC} mice to experimental DSS-induced IBD

Hnf4a^{ΔIEpC} mice showed an increased susceptibility to DSS-induced IBD compared with *Hnf4a*^{F/F} mice (n=14 for each group). Only 3 days after DSS treatment, *Hnf4a*^{ΔIEpC} mice showed significant differences in the extent of body weight loss compared with *Hnf4a*^{F/F} mice (Fig. 5A). Body weight changes in *Hnf4a*^{ΔIEpC} and *Hnf4a*^{F/F} mice were 83.1 ± 7.1 % and 98.1 ± 4.3 %, respectively at day 5 after DSS treatment relative to their initial weight (Fig. 5B). Colon length of *Hnf4a*^{ΔIEpC} mice with DSS treatment was considerably shortened compared with *Hnf4a*^{F/F} mice and control mice without DSS treatment (Fig. 5, C and D). At day 5, the colon length of *Hnf4a*^{ΔIEpC} and *Hnf4a*^{F/F} mice were 6.1 ± 1.1 cm and 8.5 ± 0.6 cm, respectively. *Hnf4a*^{ΔIEpC} mice showed more severe clinical symptoms such as diarrhea and bleeding compared to *Hnf4a*^{F/F} mice (data not shown). Histological analysis of *Hnf4a*^{ΔIEpC} colonic tissue did not show significant morphological changes without DSS-treatment (Fig. 6, A and B). However, following 5-day DSS administration *Hnf4a*^{ΔIEpC} mice demonstrated absence of epithelium and intensive submucosal infiltration of inflammatory cells compared with DSS-treated *Hnf4a*^{F/F} mice (Fig. 6, C and D). Histological score in *Hnf4a*^{ΔIEpC} mice was significantly higher compared with *Hnf4a*^{F/F} mice following 5-day DSS treatment (Fig. 6E). These findings indicate that HNF4α in the intestinal epithelial cells has a protective role against DSS-induced IBD.

Analysis of cytokine expression levels in DSS-induced IBD

To analyze cytokine gene expression levels in *Hnf4a*^{F/F} and *Hnf4a*^{ΔIEpC} mice with or without 5-day DSS treatment, qPCR was performed. IL-1β, IL-6, IL-10, TNFα, IFNγ, iNOS, CCR2, MCP-1, and ICAM-1 mRNA levels were elevated in colon tissues of *Hnf4a*^{F/F} and *Hnf4a*^{ΔIEpC} mice after 5-day DSS treatment (Fig. 7). IL-6, IL-10, iNOS, MCP-1, and ICAM-1 mRNA expression showed no significant differences between *Hnf4a*^{F/F} and *Hnf4a*^{ΔIEpC} mice. However, there were significant differences in IL-1β, TNFα, IFNγ, and CCR2 gene expression between *Hnf4a*^{F/F} and *Hnf4a*^{ΔIEpC} mice after DSS treatment. Thus, lack of HNF4α in intestinal epithelium resulted in enhanced expression of IL-1β, TNFα, IFNγ, and CCR2 mRNA levels by DSS treatment. These data suggest that HNF4α in intestinal epithelium may have an important role in the regulation of chemokine signaling during insults that result in increased inflammation.

The expression of mucins, aquaporins, and meprins is altered in the colon of *Hnf4a*^{ΔIEpC} mice

Due to the decrease in mucous secretion in *Hnf4a*^{ΔIEpC} mice as revealed by electron microscopy and PAS and Alcian blue staining the expression of mucin (Muc), aquaporins (Aqp), and meprins (Mep) mRNAs were measured by qPCR. Loss of HNF4α mRNA in colon from *Hnf4a*^{ΔIEpC} mice was confirmed by qPCR (Table 2). As a positive control, the expression of meprin 1α (*Mep1a*), a direct target gene of HNF4α (33) and a metalloproteinase (38), was markedly decreased in *Hnf4a*^{ΔIEpC} mice. Similarly, decreased expression of *Mep1β*, a gene related to *Mep1a*, was observed in *Hnf4a*^{ΔIEpC} mice. Since the colon plays a major role in absorption of water, the expression of aquaporins (Aqp) that are involved in permeability of water and small solutes (39,40) was also investigated. The mRNA expression of Aqp1 and Aqp8 was markedly reduced, and that of Aqp4 was slightly increased in *Hnf4a*^{ΔIEpC} mice. Mucin is involved in disorders of the gastrointestinal tract and colorectal cancer (41,42). The expression of Muc3 was markedly decreased while Muc1 was increased, and Muc4, Muc5AC, Muc5B, and Muc6 were slightly increased in *Hnf4a*^{ΔIEpC} mice.

***In vivo* intestinal permeability in DSS-induced IBD**

Mucin molecules have been shown to be critical in gastrointestinal barrier function; mucin molecules prevent bacterial colonization and increase bacterial clearance and serve to neutralize the acidic environment of the luminal colon. Due to the severe alteration in mucin gene expression and mucous secretions, intestinal permeability was assessed in *Hnf4a*^{F/F} and *Hnf4a*^{ΔIEpC} mice (Fig. 8). Using a FITC-labeled-dextran method, there was no significant difference in intestinal permeability between *Hnf4a*^{F/F} and *Hnf4a*^{ΔIEpC} mice without DSS-treatment. However, upon DSS treatment, *Hnf4a*^{ΔIEpC} mice showed a significantly higher permeability compared with *Hnf4a*^{F/F} mice and both *Hnf4a*^{F/F} and *Hnf4a*^{ΔIEpC} mice after 3-day DSS treatment showed a significantly higher permeability compared with untreated mice at 2, 4, and 8 hr after FITC-dextran administration. These results suggest that *Hnf4a*^{ΔIEpC} mice may be more susceptible to colon injury due to increase in intestinal permeability following an inflammatory insult.

DISCUSSION

Recently, it was reported that several nuclear receptors have a crucial role in the pathogenesis of IBD. In the present study intestinal samples from IBD patients demonstrated a significant decrease in the levels of mRNAs encoding HNF4α, MR, PPARγ, and PXR. The decrease in MR, PPARγ, and PXR is consistent with earlier studies (5,7,10,11,43,44). However, the relationship between HNF4α and IBD has not been reported. HNF4α is abundantly expressed in small intestine and colon. The HNF4α protein is also expressed in the nucleus of mucosal epithelial cells of intestine and colon (17), but the function of intestinal HNF4α is not known in contrast to hepatic HNF4α. Therefore, intestinal epithelial cell-specific *Hnf4a*-null mice, *Hnf4a*^{ΔIEpC}, were generated and the loss of HNF4α mRNA and protein was clearly observed in the small intestine and colon.

To examine the role of HNF4α in IBD, a DSS-induced IBD model was performed with *Hnf4a*^{F/F} and *Hnf4a*^{ΔIEpC} mice. As an experimental animal model, administration of dextran sulfate sodium (DSS) in the drinking water is widely used to induce IBD (36,45). DSS is a sulfated polymer that induces mucosal injury and results in inflammatory bowel disease-like colitis. The first insult occurring in the colonic mucosa is known to be the breakdown of the epithelial mucosal barrier and this breakdown of the intestinal barrier defense is thought to be important in pathogenesis of IBD (46,47). When mice were exposed to DSS treatment for 7 days, HNF4α expression was markedly decreased at both the mRNA and protein levels similar to human IBD patients. In agreement with a critical role for HNF4α in IBD, *Hnf4a*^{ΔIEpC} mice demonstrated an increased susceptibility to DSS-induced colitis compared with *Hnf4a*^{F/F} mice as assessed by body weight, colon length, and histological analysis. In addition, prolonged treatment with DSS decreased the survival of *Hnf4a*^{ΔIEpC}, whereas no change was observed in *Hnf4a*^{F/F} mice (data not shown). In the mucosa of patients with IBD, several proinflammatory and immune-regulatory cytokines are upregulated (48). The increased levels of IL-1β and TNFα, as one of major proinflammatory cytokines, were detected in mucosal specimens from patients with IBD (49–51). Consistent with the increase in susceptibility to IBD, several cytokines were significantly increased in *Hnf4a*^{ΔIEpC} mice following DSS treatment compared to DSS-treated *Hnf4a*^{F/F} mice (IL-1β, TNFα, IFNγ, and CCR2). Recently, a crosstalk between HNF4α and nuclear factor κB (NF-κB), a major regulatory gene in the inflammatory signaling pathway, was reported (52–54). It is possible that NF-κB-mediated crosstalk with HNF4α in intestine might be related to increase in cytokine expression in the absence of *Hnf4a*, but the mechanistic link is still unclear.

Also, altered expression of several mucins and aquaporins were found. Relative mRNA expression of Muc3, Aqp1, Aqp8, and Mep1α and 1β in the colon of *Hnf4a*^{ΔIEpC} mice was markedly decreased. Other genes, such as Muc4, Muc5AC, Muc5B, Muc6, and Aqp4, were

slightly induced less than two-fold in *Hnf4a*^{ΔIEpC} mice. Mucins are divided into two major classes by their structure and function; membrane-bound and secreted gel-forming mucins, respectively (41,42,55). Muc3 is a membrane-bound protein and the expression is also decreased in embryonic colon-specific *Hnf4a*-null mice. In agreement with this result, HNF4α binds to the upstream promoter region of the Muc3 gene *in vivo* (34). Several mucin genes including Muc3 are clustered at human chromosome 7q22 which was predicted to be a susceptibility locus for inflammatory bowel disease (IBD) (56). In addition, an association of rare alleles of the Muc3 gene and ulcerative colitis, a common form of IBD, was also suggested (57), indicating that HNF4α might be partly involved in IBD by regulating the expression of Muc3. Muc1 is a membrane-bound mucin (41,42,55) and its expression was strongly increased in the colon of *Hnf4a*^{ΔIEpC} mice. The expression of Muc1 is very low in normal intestinal epithelial cells, but increased in colorectal carcinoma (58,59). The cytoplasmic domain of Muc1 has the potential to associate with β-catenin (60,61) and thus, overexpression of Muc1 in the colon of *Hnf4a*^{ΔIEpC} mice might have a role in the development of colon cancer. Recently, it was reported that IL-10-deficient mice, a widely accepted mouse model of IBD, crossed to Muc1 overexpressing mice, accelerated the pathogenesis of IBD (62). It was previously demonstrated that MUC1 can act as a chemotactic agent capable of recruiting inflammatory cells. In addition lectin receptors on macrophages are capable of binding to MUC1 and activating the innate immune cells. Therefore, the dysregulation of mucin expression may have a profound effect in the innate immune system, thus increasing the susceptibility of the *Hnf4a*^{ΔIEpC} mice to inflammatory insults (63–65).

Aqp8 is expressed gastrointestinal tract including colon (66,67) and *Aqp8*-null mice only exhibited a minor phenotype (68). However, expression of Aqp8 was decreased in a DSS-treated mice (69) and colorectal tumors (70). Similar to Aqp8, Aqp1 is also expressed in the gastrointestinal tract (66). Of interest, *Aqp1*-null mice were 10–15% smaller than wild-type mice (66). Since body weight of *Hnf4a*^{ΔIEpC} mice was unchanged as compared to *Hnf4a*^{F/F} mice (data not shown), decreased expression of Aqp1 in the colon might not be critical for the loss of body weight. However, the role of Aqp1 in colon has not been elucidated. Meprins are metalloproteinases that are highly expressed in the intestinal epithelial cells and composed of two related subunits, α and β, leading to homo- or hetero-oligomeric proteins (38). These enzymes degrade a wide range of proteins of extracellular matrix and biologically active peptides (71,72) and have been shown to be involved in cancer and intestinal inflammation (38,73,74). Since the expression of Mep1α is known to be dependent on HNF4α expression and an HNF4α binding site in the promoter region (33), Mep1α could be a direct target for HNF4α in the colon and thus may be of value to determine whether HNF4α is involved in Mep1β activation. Furthermore, since *Mep1β*-null mice only exhibited decreased levels of Mep1α in the intestine (75), the physiological role of decreased expression of Mep1α and 1β in the colon remains unknown. However, altered expression of other mucins and aquaporins may suggest a relationship with IBD.

Another possible molecular mechanism by which HNF4α influences IBD is through the regulation of intestinal permeability. *Hnf4a*^{ΔIEpC} mice showed a markedly higher intestinal permeability compared with *Hnf4a*^{F/F} mice after DSS treatment. This increased intestinal permeability in *Hnf4a*^{ΔIEpC} mice after DSS treatment is consistent with increased histological inflammatory status and altered gene expression of mucins and aquaporins. During intestinal inflammatory insults, improvement in mucosal integrity related with HNF4α may reduce intestinal inflammation and protect against endotoxins or xenobiotics like DSS in intestinal tissue.

In conclusion, mice lacking expression of the HNF4α gene in intestinal epithelial cells were successfully developed. These mice exhibited decreased levels of polysaccharides and acidic mucopolysaccharides and altered expression of several genes encoding mucins and aquaporins.

Gut-specific *Hnf4α*-null mice showed higher susceptibility to DSS-induced IBD as a result of increased permeability of the epithelial barrier. Thus, HNF4α may have an important protective role in inflammatory bowel disease.

Acknowledgements

This project was funded by the National Cancer Institute Intramural Research Program and by NCI contract N01-CO-12400 (KN). YS was funded by a fellowship from the American Cancer Society. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

Abbreviations

HNF4α	hepatocyte nuclear factor 4α
IBD	inflammatory bowel disease
CD	Crohn's disease
UC	ulcerative colitis
DSS	dextran sulfate sodium
IEpC	intestinal epithelial cell
F	floxed allele
MODY1	maturity onset diabetes of the young 1
H&E	hematoxylin and eosin
PAS	periodic acid-Schiff
Muc	mucin
Aqp	aquaporin
Mep	meprin
FITC	fluorescein isothiocyanate

References

1. Podolsky DK. Inflammatory bowel disease. *N Engl J Med* 2002;347:417–429. [PubMed: 12167685]

2. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. *Nat Rev Immunol* 2003;3:521–533. [PubMed: 12876555]
3. Froicu M, Weaver V, Wynn TA, et al. A crucial role for the vitamin D receptor in experimental inflammatory bowel diseases. *Mol Endocrinol* 2003;17:2386–2392. [PubMed: 14500760]
4. Lim WC, Hanauer SB, Li YC. Mechanisms of disease: vitamin D and inflammatory bowel disease. *Nat Clin Pract Gastroenterol Hepatol* 2005;2:308–315. [PubMed: 16265284]
5. Dubuquoy L, Jansson EA, Deeb S, et al. Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. *Gastroenterology* 2003;124:1265–1276. [PubMed: 12730867]
6. Katayama K, Wada K, Nakajima A, et al. A novel PPAR gamma gene therapy to control inflammation associated with inflammatory bowel disease in a murine model. *Gastroenterology* 2003;124:1315–1324. [PubMed: 12730872]
7. Adachi M, Kurotani R, Morimura K, et al. Peroxisome proliferator activated receptor gamma in colonic epithelial cells protects against experimental inflammatory bowel disease. *Gut* 2006;55:1104–1113. [PubMed: 16547072]
8. Cuzzocrea S, Di Paola R, Mazzon E, et al. Role of endogenous and exogenous ligands for the peroxisome proliferators activated receptors alpha (PPAR-alpha) in the development of inflammatory bowel disease in mice. *Lab Invest* 2004;84:1643–1654. [PubMed: 15492755]
9. Bassaganya-Riera J, Reynolds K, Martino-Catt S, et al. Activation of PPAR gamma and delta by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease. *Gastroenterology* 2004;127:777–791. [PubMed: 15362034]
10. Langmann T, Moehle C, Mauerer R, et al. Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. *Gastroenterology* 2004;127:26–40. [PubMed: 15236169]
11. Shah YM, Ma X, Morimura K, et al. Pregnane X receptor activation ameliorates DSS-induced inflammatory bowel disease via inhibition of NF-kappaB target gene expression. *Am J Physiol Gastrointest Liver Physiol* 2007;292:G1114–1122. [PubMed: 17170021]
12. Schottelius A, Wedel S, Weltrich R, et al. Higher expression of glucocorticoid receptor in peripheral mononuclear cells in inflammatory bowel disease. *Am J Gastroenterol* 2000;95:1994–1999. [PubMed: 10950048]
13. Stange EF. Glucocorticoid receptor activity in inflammatory bowel disease: hindsight or foresight? *Eur J Clin Invest* 1999;29:278–279. [PubMed: 10231338]
14. Sladek FM, Zhong WM, Lai E, et al. Liver-enriched transcription factor HNF-4 is a novel member of the steroid hormone receptor superfamily. *Genes Dev* 1990;4:2353–2365. [PubMed: 2279702]
15. Schrem H, Klempnauer J, Borlak J. Liver-enriched transcription factors in liver function and development. Part I: the hepatocyte nuclear factor network and liver-specific gene expression. *Pharmacol Rev* 2002;54:129–158. [PubMed: 11870262]
16. Drewes T, Senkel S, Holewa B, et al. Human hepatocyte nuclear factor 4 isoforms are encoded by distinct and differentially expressed genes. *Mol Cell Biol* 1996;16:925–931. [PubMed: 8622695]
17. Jiang S, Tanaka T, Iwanari H, et al. Expression and localization of P1 promoter-driven hepatocyte nuclear factor-4alpha (HNF4alpha) isoforms in human and rats. *Nucl Recept* 2003;1:5. [PubMed: 12952540]
18. Chen WS, Manova K, Weinstein DC, et al. Disruption of the HNF-4 gene, expressed in visceral endoderm, leads to cell death in embryonic ectoderm and impaired gastrulation of mouse embryos. *Genes Dev* 1994;8:2466–2477. [PubMed: 7958910]
19. Hayhurst GP, Lee YH, Lambert G, et al. Hepatocyte nuclear factor 4alpha (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis. *Mol Cell Biol* 2001;21:1393–1403. [PubMed: 11158324]
20. Inoue Y, Hayhurst GP, Inoue J, et al. Defective ureagenesis in mice carrying a liver-specific disruption of hepatocyte nuclear factor 4alpha (HNF4alpha). HNF4alpha regulates ornithine transcarbamylase in vivo. *J Biol Chem* 2002;277:25257–25265. [PubMed: 11994307]
21. Rhee J, Inoue Y, Yoon JC, et al. Regulation of hepatic fasting response by PPARgamma coactivator-1alpha (PGC-1): requirement for hepatocyte nuclear factor 4alpha in gluconeogenesis. *Proc Natl Acad Sci U S A* 2003;100:4012–4017. [PubMed: 12651943]

22. Kamiya A, Inoue Y, Kodama T, et al. Hepatocyte nuclear factors 1alpha and 4alpha control expression of proline oxidase in adult liver. *FEBS Lett* 2004;578:63–68. [PubMed: 15581617]
23. Inoue Y, Yu AM, Yim SH, et al. Regulation of bile acid biosynthesis by hepatocyte nuclear factor 4alpha. *J Lipid Res* 2006;47:215–227. [PubMed: 16264197]
24. Inoue Y, Peters LL, Yim SH, et al. Role of hepatocyte nuclear factor 4alpha in control of blood coagulation factor gene expression. *J Mol Med* 2006;84:334–344. [PubMed: 16389552]
25. Miura A, Yamagata K, Kakei M, et al. Hepatocyte nuclear factor-4alpha is essential for glucose-stimulated insulin secretion by pancreatic beta-cells. *J Biol Chem* 2006;281:5246–5257. [PubMed: 16377800]
26. Gupta RK, Vatamaniuk MZ, Lee CS, et al. The MODY1 gene HNF-4alpha regulates selected genes involved in insulin secretion. *J Clin Invest* 2005;115:1006–1015. [PubMed: 15761495]
27. Ginsburg GS, Ozer J, Karathanasis SK. Intestinal apolipoprotein AI gene transcription is regulated by multiple distinct DNA elements and is synergistically activated by the orphan nuclear receptor, hepatocyte nuclear factor 4. *J Clin Invest* 1995;96:528–538. [PubMed: 7615825]
28. Ochoa A, Bovard-Houppermans S, Zakin MM. Human apolipoprotein A-IV gene expression is modulated by members of the nuclear hormone receptor superfamily. *Biochim Biophys Acta* 1993;1210:41–47. [PubMed: 8257717]
29. Antes TJ, Levy-Wilson B. HNF-3 beta, C/EBP beta, and HNF-4 act in synergy to enhance transcription of the human apolipoprotein B gene in intestinal cells. *DNA Cell Biol* 2001;20:67–74. [PubMed: 11244563]
30. Swenson ES, Mann EA, Jump ML, et al. Hepatocyte nuclear factor-4 regulates intestinal expression of the guanylin/heat-stable toxin receptor. *Am J Physiol* 1999;276:G728–736. [PubMed: 10070050]
31. Tegude H, Schnabel A, Zanger UM, et al. Molecular Mechanism of Basal CYP3A4 Regulation by Hepatocyte Nuclear Factor 4{alpha}: Evidence for Direct Regulation in the Intestine. *Drug Metab Dispos* 2007;35:946–954. [PubMed: 17344340]
32. Olsen L, Bressendorff S, Troelsen JT, et al. Differentiation-dependent activation of the human intestinal alkaline phosphatase promoter by HNF-4 in intestinal cells. *Am J Physiol Gastrointest Liver Physiol* 2005;289:G220–226. [PubMed: 15831710]
33. Stegmann A, Hansen M, Wang Y, et al. Metabolome, transcriptome, and bioinformatic cis-element analyses point to HNF-4 as a central regulator of gene expression during enterocyte differentiation. *Physiol Genomics* 2006;27:141–155. [PubMed: 16868071]
34. Garrison WD, Battle MA, Yang C, et al. Hepatocyte nuclear factor 4alpha is essential for embryonic development of the mouse colon. *Gastroenterology* 2006;130:1207–1220. [PubMed: 16618389]
35. Madison BB, Dunbar L, Qiao XT, et al. Cis elements of the villin gene control expression in restricted domains of the vertical (crypt) and horizontal (duodenum, cecum) axes of the intestine. *J Biol Chem* 2002;277:33275–33283. [PubMed: 12065599]
36. Cooper HS, Murthy SN, Shah RS, et al. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. *Lab Invest* 1993;69:238–249. [PubMed: 8350599]
37. Shah YM, Morimura K, Gonzalez FJ. Expression of peroxisome proliferator-activated receptor-gamma in macrophage suppresses experimentally induced colitis. *Am J Physiol Gastrointest Liver Physiol* 2007;292:G657–666. [PubMed: 17095756]
38. Bond JS, Matters GL, Banerjee S, et al. Meprin metalloprotease expression and regulation in kidney, intestine, urinary tract infections and cancer. *FEBS Lett* 2005;579:3317–3322. [PubMed: 15943977]
39. King LS, Kozono D, Agre P. From structure to disease: the evolving tale of aquaporin biology. *Nat Rev Mol Cell Biol* 2004;5:687–698. [PubMed: 15340377]
40. Verkman AS, Mitra AK. Structure and function of aquaporin water channels. *Am J Physiol Renal Physiol* 2000;278:F13–28. [PubMed: 10644652]
41. Jass JR, Walsh MD. Altered mucin expression in the gastrointestinal tract: a review. *J Cell Mol Med* 2001;5:327–351. [PubMed: 12067494]
42. Byrd JC, Bresalier RS. Mucins and mucin binding proteins in colorectal cancer. *Cancer Metastasis Rev* 2004;23:77–99. [PubMed: 15000151]
43. Amasheh S, Barmeyer C, Koch CS, et al. Cytokine-dependent transcriptional down-regulation of epithelial sodium channel in ulcerative colitis. *Gastroenterology* 2004;126:1711–1720. [PubMed: 15188166]

44. Takahashi KI, Fukushima K, Sasano H, et al. Type II 11 β -hydroxysteroid dehydrogenase expression in human colonic epithelial cells of inflammatory bowel disease. *Dig Dis Sci* 1999;44:2516–2522. [PubMed: 10630506]
45. Seril DN, Liao J, Yang GY, et al. Oxidative stress and ulcerative colitis-associated carcinogenesis: studies in humans and animal models. *Carcinogenesis* 2003;24:353–362. [PubMed: 12663492]
46. Sartor RB. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease. *Gastroenterol Clin North Am* 1995;24:475–507. [PubMed: 8809232]
47. Luger N, Kucharzik T, Stoll R, et al. Current concept of the role of monocytes/macrophages in inflammatory bowel disease--balance of proinflammatory and immunosuppressive mediators. *Ital J Gastroenterol Hepatol* 1998;30:338–344. [PubMed: 9759608]
48. Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. *Annu Rev Med* 2000;51:289–298. [PubMed: 10774465]
49. Brynkvog J, Tvede N, Andersen CB, et al. Increased concentrations of interleukin 1 beta, interleukin-2, and soluble interleukin-2 receptors in endoscopic mucosal biopsy specimens with active inflammatory bowel disease. *Gut* 1992;33:55–58. [PubMed: 1740278]
50. Cappello M, Keshav S, Prince C, et al. Detection of mRNAs for macrophage products in inflammatory bowel disease by in situ hybridisation. *Gut* 1992;33:1214–1219. [PubMed: 1427374]
51. Reinecker HC, Steffen M, Witthoef T, et al. Enhanced secretion of tumour necrosis factor- α , IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. *Clin Exp Immunol* 1993;94:174–181. [PubMed: 8403503]
52. De Bosscher K, Vanden Berghe W, Haegeman G. Cross-talk between nuclear receptors and nuclear factor kappaB. *Oncogene* 2006;25:6868–6886. [PubMed: 17072333]
53. Guo H, Wei J, Inoue Y, et al. Serine/threonine phosphorylation regulates HNF-4 α -dependent redox-mediated iNOS expression in hepatocytes. *Am J Physiol Cell Physiol* 2003;284:C1090–1099. [PubMed: 12466152]
54. Nikolaidou-Neokosmidou V, Zannis VI, Kardassis D. Inhibition of hepatocyte nuclear factor 4 transcriptional activity by the nuclear factor kappaB pathway. *Biochem J* 2006;398:439–450. [PubMed: 16771709]
55. Moniaux N, Escande F, Porchet N, et al. Structural organization and classification of the human mucin genes. *Front Biosci* 2001;6:D1192–1206. [PubMed: 11578969]
56. Satsangi J, Parkes M, Louis E, et al. Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. *Nat Genet* 1996;14:199–202. [PubMed: 8841195]
57. Kyo K, Parkes M, Takei Y, et al. Association of ulcerative colitis with rare VNTR alleles of the human intestinal mucin gene, MUC3. *Hum Mol Genet* 1999;8:307–311. [PubMed: 9931338]
58. Nakamori S, Ota DM, Cleary KR, et al. MUC1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma. *Gastroenterology* 1994;106:353–361. [PubMed: 7905449]
59. Baldus SE, Monig SP, Hanisch FG, et al. Comparative evaluation of the prognostic value of MUC1, MUC2, sialyl-Lewis(a) and sialyl-Lewis(x) antigens in colorectal adenocarcinoma. *Histopathology* 2002;40:440–449. [PubMed: 12010364]
60. Yamamoto M, Bharti A, Li Y, et al. Interaction of the DF3/MUC1 breast carcinoma-associated antigen and beta-catenin in cell adhesion. *J Biol Chem* 1997;272:12492–12494. [PubMed: 9139698]
61. Li Y, Bharti A, Chen D, et al. Interaction of glycogen synthase kinase 3 β with the DF3/MUC1 carcinoma-associated antigen and beta-catenin. *Mol Cell Biol* 1998;18:7216–7224. [PubMed: 9819408]
62. Beatty PL, Plevy SE, Sepulveda AR, et al. Cutting edge: transgenic expression of human MUC1 in IL-10 $^{-/-}$ mice accelerates inflammatory bowel disease and progression to colon cancer. *J Immunol* 2007;179:735–739. [PubMed: 17617560]
63. Monti P, Leone BE, Zerbi A, et al. Tumor-derived MUC1 mucins interact with differentiating monocytes and induce IL-10 high IL-12 low regulatory dendritic cell. *J Immunol* 2004;172:7341–7349. [PubMed: 15187110]

64. Hiltbold EM, Vlad AM, Ciborowski P, et al. The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells. *J Immunol* 2000;165:3730–3741. [PubMed: 11034378]
65. Herbert LM, Grosso JF, Dorsey M Jr, et al. A unique mucin immunoenhancing peptide with antitumor properties. *Cancer Res* 2004;64:8077–8084. [PubMed: 15520219]
66. Ma T, Verkman AS. Aquaporin water channels in gastrointestinal physiology. *J Physiol* 1999;517 (Pt 2):317–326. [PubMed: 10332084]
67. Koyama Y, Yamamoto T, Kondo D, et al. Molecular cloning of a new aquaporin from rat pancreas and liver. *J Biol Chem* 1997;272:30329–30333. [PubMed: 9374520]
68. Yang B, Song Y, Zhao D, et al. Phenotype analysis of aquaporin-8 null mice. *Am J Physiol Cell Physiol* 2005;288:C1161–1170. [PubMed: 15647389]
69. Hardin JA, Wallace LE, Wong JF, et al. Aquaporin expression is downregulated in a murine model of colitis and in patients with ulcerative colitis, Crohn's disease and infectious colitis. *Cell Tissue Res* 2004;318:313–323. [PubMed: 15338270]
70. Fischer H, Stenling R, Rubio C, et al. Differential expression of aquaporin 8 in human colonic epithelial cells and colorectal tumors. *BMC Physiol* 2001;1:1. [PubMed: 11231887]
71. Bertenshaw GP, Turk BE, Hubbard SJ, et al. Marked differences between metalloproteases meprin A and B in substrate and peptide bond specificity. *J Biol Chem* 2001;276:13248–13255. [PubMed: 11278902]
72. Kruse MN, Becker C, Lottaz D, et al. Human meprin alpha and beta homo-oligomers: cleavage of basement membrane proteins and sensitivity to metalloprotease inhibitors. *Biochem J* 2004;378:383–389. [PubMed: 14594449]
73. Lottaz D, Maurer CA, Hahn D, et al. Nonpolarized secretion of human meprin alpha in colorectal cancer generates an increased proteolytic potential in the stroma. *Cancer Res* 1999;59:1127–1133. [PubMed: 10070973]
74. Matters GL, Bond JS. Expression and regulation of the meprin beta gene in human cancer cells. *Mol Carcinog* 1999;25:169–178. [PubMed: 10411143]
75. Norman LP, Jiang W, Han X, et al. Targeted disruption of the meprin beta gene in mice leads to underrepresentation of knockout mice and changes in renal gene expression profiles. *Mol Cell Biol* 2003;23:1221–1230. [PubMed: 12556482]

Fig. 1.

Nuclear receptor gene expression in intestinal samples from human IBD patients. The gene expression of hepatocyte nuclear factor 4 α (HNF4 α), farnesoid X receptor (FXR), liver X receptor (LXR), mineralocorticoid receptor (MR), peroxisome proliferator-activated receptor α , β , γ (PPAR α , PPAR β , PPAR γ), vitamin D receptor (VDR), and pregnane X receptor (PXR) were performed by qPCR to assess their gene expression in human IBD patient tissues. Mann-Whitney U test was performed to assess significant differences between normal and patients group. P values are expressed as *, $P < 0.05$, ** $P < 0.01$, and *** $P < 0.001$.

Fig. 2.

HNF4α gene expression after DSS treatment. Expression of HNF4α mRNA, as measured by quantitative real-time PCR (qPCR), was decreased at day 7 after 2.5% DSS and 5% DSS treatment (A). Expression of HNF4α mRNA was decreased at day 1, 3, 5, and 7 after 2.5% DSS treatment (B). HNF4α protein, as measured by western blot analysis, was also decreased at day 1, 3, 5, and 7 after 2.5% DSS treatment and relative density to β-actin was decreased at day 1, 3, 5, and 7 after 2.5% DSS treatment (C). Both relative mRNA and protein levels of HNF4α were decreased after DSS treatment. Data represent the mean value ± standard deviations, ***, $p < 0.001$ compared with control mice.

Fig. 3. Generation of the intestinal epithelial cells-specific *Hnf4α*-null, *Hnf4α^{ΔEpC}* mice. Schematic of generation of intestinal specific *Hnf4α*-null mice (A) and their genotypes by PCR (B) using microsomal epoxide hydrolase (mEH) primers as a positive control for amplification. The loss of intestine-specific *HNF4α* gene were analyzed by northern blot analysis (C) and immunohistochemical analysis (D). Immunohistochemistry analysis with *HNF4α* antibody of *Hnf4α^{F/F}* (D; a, c, and e) and *Hnf4α^{ΔEpC}* (D; b, d, and f) mice in duodenum (a and b), jejunum (c and d), ileum (e and f). Note the loss of *HNF4α*-positive cells in nucleus from *Hnf4α^{F/F}* mice. *HNF4α* related gene expression as assessed by northern blot analysis in whole intestine of *Hnf4α^{F/F}* and *Hnf4α^{ΔEpC}* mice. Pooled total RNA ($n=7$ for each genotype) was isolated from liver, kidney, duodenum, jejunum, ileum, and colon (L, K, D, J, I, and C, respectively).

Fig. 4.

Histological and immunohistochemical analysis of the intestine in *Hnf4α^{F/F}* and *Hnf4α^{ΔIEpC}* mice by H&E stained intestine sections (A), ultrastructure (B), PAS, and alcian blue stain (C). H&E stained intestine sections from *Hnf4α^{F/F}* (A; left panel; a, c, e, and g) and *Hnf4α^{ΔIEpC}* (A; right panel; b, d, f, and h) mice (original magnification X 200) and ultrastructure of the colon from *Hnf4α^{F/F}* (i) and *Hnf4α^{ΔIEpC}* (j) mice. N; nucleus, MG; mucous granules. Immunohistochemistry of HNF4α, and polysaccharide and acidic mucopolysaccharide stain in the colon of *Hnf4α^{F/F}* and *Hnf4α^{ΔIEpC}* mice (C). Immunohistochemistry against HNF4α antibody (k and l), PAS (m and n), and Alcian blue stain (o and p) from in the colon of *Hnf4α^{F/F}* (C; left panel) and *Hnf4α^{ΔIEpC}* (C; right panel) mice.

Fig. 5.

Assessment of DSS-induced IBD in $Hnf4\alpha^{F/F}$ and $Hnf4\alpha^{\Delta IEpC}$ mice. Lack of HNF4 α in intestinal epithelial cells is associated with increased susceptibility to DSS-induced IBD. Daily changes in body weight following DSS treatment (A), loss of body weight at day 5 after DSS treatment (B), picture of the isolated colon from $Hnf4\alpha^{F/F}$ and $Hnf4\alpha^{\Delta IEpC}$ mice with or without DSS treatment (C), and colon length, which was shortened by severe IBD (D). Data represent the mean value $\pm$ standard deviations of $n=14$ for each group, *, $p<0.05$, and ***, $p<0.001$ compared with DSS-treated $Hnf4\alpha^{F/F}$ mice.

Fig. 6. Histological assessment of 5-day DSS or control treatment in *Hnf4 α ^{F/F}* and *Hnf4 α ^{Δ IEpC}* mice. H&E stained colon sections from *Hnf4 α ^{F/F}* (A) and *Hnf4 α ^{Δ IEpC}* (B) mice following control treatment, *Hnf4 α ^{F/F}* (C) and *Hnf4 α ^{Δ IEpC}* (D) mice after 5-day DSS treatment. Histological score was analyzed from colonic H&E stained sections of *Hnf4 α ^{F/F}* and *Hnf4 α ^{Δ IEpC}* mice after 5-day DSS treatment (E). Data represent the mean value $\pm$ standard deviations, *, $p < 0.05$ compared with DSS-treated *Hnf4 α ^{F/F}* mice.

Fig. 7.

Cytokine gene expression from colon tissue following 5-day DSS or control treatment in *Hnf4α^{F/F}* and *Hnf4α^{ΔIEpC}* mice. IL-1β, IL-6, IL-10, TNFα, IFNγ, iNOS, CCR2, MCP-1, and ICAM-1 mRNA expressions were analyzed by qPCR. Expression was normalized to 36B4. Data represent the mean value ± standard deviations of n=8 for each group, *, $p < 0.05$ compared with DSS-treated *Hnf4α^{F/F}* mice.

Fig. 8.

In vivo intestinal permeability assay. Intestinal permeability using a FITC-labeled-dextran method were measured at 2, 4, and 8 hr of fluorescence units after FITC-dextran oral administration following 3-day DSS treatment between *Hnf4a*^{F/F} and *Hnf4a*^{ΔIEpC} mice. Data represent the mean value ± standard deviations, * $p < 0.05$.

Table 1

Human IBD patient description

Patient #	Sex	Age	Diagnosis	Tissue	Patient #	Sex	Age	Diagnosis	Tissue
1	Male	78	Normal	Colon	25	Male	29	CD	Ileum
2	Male	47	Normal	Colon	26	Male	42	CD	Sm Intest
3	Female	31	Normal	Colon	27	Female	39	CD	Ileum
4	Male	54	Normal	Colon	28	Male	54	UC	Colon
5	Male	37	Normal	Ileum	29	Male	59	UC	Colon
6	Female	61	Normal	Ileum	30	Male	72	UC	Colon
7	Male	56	CD	Colon	31	Male	41	UC	Colon
8	Male	33	CD	Colon	32	Female	54	UC	Rectum
9	Female	46	CD	Colon	33	Female	72	UC	Colon
10	Female	51	CD	Colon	34	Female	36	UC	Colon
11	Female	31	CD	Ileum	35	Male	56	UC	Colon
12	Male	37	CD	Ileum	36	Male	31	UC	Rectum
13	Male	48	CD	Ileum	37	Male	23	UC	Colon
14	Female	65	CD	Ileum	38	Male	42	UC	Colon
15	Female	26	CD	Ileum	39	Male	42	UC	Colon
16	Male	33	Cecum	Sm Intest	40	Male	68	UC	Rectum
17	Female	45	CD	Ileum	41	Male	45	UC	Rectum
18	Male	64	CD	Ileum	42	Female	60	UC	Colon
19	Female	31	CD	Ileum	43	Male	33	UC	Colon
20	Male	35	CD	Colon	44	Female	27	UC	Colon
21	Male	20	CD	Ileum	45	Male	57	UC	Rectum
22	Male	41	CD	Colon	46	Female	35	UC	Colon
23	Female	21	CD	Colon	47	Female	30	UC	Colon
24	Male	41	CD	Colon	48	Female	26	UC	Colon

NOTE. CD: Crohn's disease, UC: ulcerative colitis, Sm Intest; small intestine.

Table 2Gene expression analysis in the colon of *Hnf4a*^{F/F} and *Hnf4a*^{ΔEpC} mice

Gene	<i>Hnf4a</i> ^{F/F}	<i>Hnf4a</i> ^{ΔEpC}
HNF4α	1.00 ± 0.16	0.01 ± 0.00 ^{***}
Muc1	1.00 ± 0.34	7.54 ± 1.42 ^{***}
Muc2	1.00 ± 0.49	0.88 ± 0.41
Muc3	1.00 ± 0.38	0.07 ± 0.05 ^{***}
Muc4	1.00 ± 0.34	1.64 ± 0.47 [*]
Muc5AC	1.00 ± 0.39	1.74 ± 0.46 [*]
Muc5B	1.00 ± 0.35	1.77 ± 0.51 [*]
Muc6	1.00 ± 0.36	1.54 ± 0.39 [*]
Aqp1	1.00 ± 0.43	0.32 ± 0.10 ^{**}
Aqp4	1.00 ± 0.33	1.50 ± 0.39 [*]
Aqp8	1.00 ± 0.21	0.15 ± 0.03 ^{***}
Mep1α	1.00 ± 0.30	0.12 ± 0.05 ^{***}
Mep1β	1.00 ± 0.32	0.10 ± 0.04 ^{***}

NOTE. Quantitative real-time PCR of colon mRNA from 2-month-old mice (n=6). All the values are means ± SD. Significant difference compared to *Hnf4a*^{F/F} mice:

^{*}, $p < 0.05$

^{**}, $p < 0.01$

^{***}, $p < 0.001$.